Supha Pharmachem Limited has formally submitted a public announcement to BSE Limited regarding the commencement of Corporate Insolvency Resolution Process (CIRP) following the National Company Law Tribunal's order dated March 17, 2026. The pharmaceutical company, formerly known as Remedium Lifecare Limited, has initiated the mandatory disclosure process under SEBI regulations.

Public Announcement and Regulatory Compliance

The company submitted the public announcement on March 20, 2025, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement formally notifies all stakeholders about the NCLT's decision to admit the company under CIRP proceedings.

Creditor Claims Process and Timeline

The Interim Resolution Professional has issued Form A public announcement inviting claims from all creditors of Supha Pharmachem Limited. The announcement establishes a clear timeline for creditor participation in the insolvency resolution process.

Interim Resolution Professional Details

Mr. Rajesh Jhunjhunwala has been appointed as the Interim Resolution Professional to oversee the CIRP proceedings. His contact details have been updated for correspondence related to the insolvency process.

Company Background and Current Status

Supha Pharmachem Limited, incorporated on February 19, 1988, under ROC Mumbai, has undergone significant changes during the insolvency process. The company has relocated its registered office from the previous Marol location to F81D, Express Zone Mall, A Wing, Goregaon (East), Mumbai - 400063.

The NCLT admission follows a substantial default of Rs. 7,47,20,079 to Boston Ivy Healthcare Solution Private Limited, with the date of default recorded as November 7, 2023. The tribunal's order has suspended the powers of the Board of Directors, with all management authority now vested with the appointed Interim Resolution Professional.

The public announcement warns that submission of false or misleading proofs of claim will attract penalties, emphasizing the serious nature of the proceedings and the need for accurate documentation from all creditors participating in the resolution process.

Supha Pharmachem Limited has announced the relocation of its registered office within Mumbai, moving from its current location in Marol to a new address in Goregaon East. The board of directors approved this significant corporate change during their meeting held on March 17, 2026.

Board Approval and Timeline

The company's board of directors considered and approved the shifting of the registered office during their meeting on Tuesday, March 17, 2026. The relocation takes effect immediately from the same date, demonstrating swift implementation of the board's decision.

Office Relocation Details

The registered office transition involves a complete change of location within Mumbai:

Regulatory Compliance

Supha Pharmachem Limited has duly informed BSE Limited about this corporate development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was signed by Whole Time Director Adarsh Munjal, who holds DIN 07304004.

Company Background

The company, formerly known as Remedium Lifecare Limited, operates under CIN L24100MH1988PLC343805. The registered office relocation represents a strategic move within Mumbai's business landscape, transitioning from the Marol Industrial Estate area to the Express Zone Mall complex in Goregaon East.

This administrative change ensures continued compliance with regulatory requirements while potentially providing enhanced operational facilities at the new location. The company maintains its commitment to transparency by promptly notifying stakeholders and regulatory authorities about this corporate development.